RAD21 and ovarian carcinoma: Deng et al. [139] discovered that a RAD21 amplification in ovarian cancer led to the epigenetic suppression of interferon signaling, promoting immune evasion and highlighting RAD21 as a potential target and biomarker for precision immunotherapy.